Mantle Cell Lymphoma

James N. Gerson, MD, discusses the watch-and-wait approach for patients with mantle cell lymphoma.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the future therapeutic landscape of mantle cell lymphoma.

Michael Wang, MD, discusses data from a phase I/II study looking at the use a triplet regimen of vorinostat, cladribine, and rituximab in patients with newly diagnosed mantle cell lymphoma.

Andrew D. Zelenetz, MD, PhD, discusses approved treatment options for patients with mantle cell lymphoma, as well as treatments coming down the pipeline.

Andrew D. Zelenetz, MD, PhD, discusses the use of emerging targeted therapies in mantle cell lymphoma.

Andre Goy, MD, MS, discusses cutting-edge CAR T-cell therapy and other groundbreaking investigations, as well as his thoughts on general developments in oncology and hematology.

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

Michael Wang, MD, discusses how the mantle cell lymphoma paradigm is facing a time of exploration, as researchers examine different therapeutic options beyond chemotherapy.

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses anticipated research in mantle cell lymphoma (MCL).

Simon Rule, MD, discusses a study comparing patients with newly diagnosed mantle cell lymphoma who receive immediate systemic treatment immediately versus patients who are closely monitored instead.

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses the heterogeneity of mantle cell lymphoma (MCL).

Michael Wang, MD, discusses resistance to CAR T-cell therapy and the next steps to overcoming this challenge in treatment for mantle cell lymphoma.

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).

The triplet regimen of vorinostat (Zolinza), cladribine, and rituximab (Rituxan) demonstrated an objective response rate of 97% and a complete response rate of 80% in newly diagnosed patients with mantle cell lymphoma.

The FDA has granted a priority review designation to a new drug application for zanubrutinib for the treatment of patients with mantle cell lymphoma who have received ≥1 prior therapy.

Peter Martin, MD, discusses a phase I trial examining the ibrutinib plus palbociclib combination in ibrutinib-resistant patients with mantle cell lymphoma.

Simon Rule, MD, PhD, discusses the current treatment options in mantle cell lymphoma and explained how anticipated research results could be integrated into the field.

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, discusses the treatment paradigm in mantle cell lymphoma (MCL).

Kieron Dunleavy, MD, discusses the current treatment paradigm in mantle call lymphoma and the emerging potential for CAR T-cell therapy.

Simon Rule, MD, PhD, professor of haematology, Plymouth University Medical School, discusses the standard of care for mantle cell lymphoma in various patient subsets.

Peter Martin, MD, discusses the need for a personalized therapeutic approach in frontline MCL treatment.

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses standard of care for younger patients with mantle cell lymphoma.

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

Yuqin Song, MD, PhD, discusses the clinical activity with zanubrutinib in patients with relapsed/refractory mantle cell lymphoma.

Rory McCulloch, MD, discusses the results of a retrospective analysis looking at rituximab, bendamustine, and cytarabine in patients with mantle cell lymphoma who have relapsed on a BTK inhibitor.